Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Short Interest Update

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) was the recipient of a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 4,540,000 shares, a decline of 17.5% from the December 31st total of 5,500,000 shares. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is presently 3.5 days.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently made changes to their positions in ZNTL. Verition Fund Management LLC raised its holdings in shares of Zentalis Pharmaceuticals by 172.1% during the third quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after purchasing an additional 951,500 shares during the last quarter. Primecap Management Co. CA grew its holdings in Zentalis Pharmaceuticals by 21.6% during the third quarter. Primecap Management Co. CA now owns 1,498,030 shares of the company’s stock worth $5,513,000 after acquiring an additional 265,690 shares during the period. GSA Capital Partners LLP raised its position in Zentalis Pharmaceuticals by 138.5% during the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after acquiring an additional 353,384 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Zentalis Pharmaceuticals by 126.3% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 229,138 shares of the company’s stock valued at $843,000 after acquiring an additional 127,868 shares during the period. Finally, XTX Topco Ltd boosted its position in Zentalis Pharmaceuticals by 8.7% in the 3rd quarter. XTX Topco Ltd now owns 194,062 shares of the company’s stock worth $714,000 after purchasing an additional 15,597 shares in the last quarter.

Analyst Ratings Changes

ZNTL has been the topic of several recent analyst reports. Guggenheim decreased their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, November 15th. UBS Group decreased their price objective on shares of Zentalis Pharmaceuticals from $5.00 to $2.20 and set a “neutral” rating on the stock in a research note on Tuesday. HC Wainwright cut their target price on Zentalis Pharmaceuticals from $20.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Wedbush reaffirmed a “neutral” rating and issued a $4.00 target price on shares of Zentalis Pharmaceuticals in a report on Friday, January 24th. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, Zentalis Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $8.58.

Zentalis Pharmaceuticals Price Performance

ZNTL stock opened at $1.89 on Thursday. Zentalis Pharmaceuticals has a 1-year low of $1.76 and a 1-year high of $18.07. The stock has a market capitalization of $134.68 million, a P/E ratio of -0.76 and a beta of 1.86. The business has a fifty day moving average price of $3.00 and a 200-day moving average price of $3.30.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. As a group, analysts anticipate that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.